Drugs / HRV Lyophilized
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02141204 Comparator | Feb → Dec 2019 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRV Lyophilized | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02141204 ↗ |
| Known as | Rotarix | “Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants” NCT02141204 ↗ |
| Modality | Vaccine | “Oral Live Attenuated Human Rotavirus (HRV) Vaccine” NCT02141204 ↗ |
| Route | Oral | “Two doses administered orally according to a 0, 1-month schedule.” NCT02141204 ↗ |